AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05649592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Hydrolipid Separation Imaging
Description: MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5.
Study NCT04554888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin Topical
Description: Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
Study NCT04554888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain
Description: Papain will be applied by 1 SPT prick thought the skin
Study NCT04554888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histamine will be applied by 1 SPT prick thought the skin
Study NCT04554888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study NCT06551883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different bowel preparation regime
Description: Patients in Group B receive the 3L of PEG in a single dose
Study NCT06551883 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: traditional bowel preparation regime
Description: Patients in Group A receive the 3L of PEG in a split dose
Study NCT05907239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Extracorporeal Shockwave Therapy
Description: We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
Study NCT05907239 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Focused Extracorporeal Shockwave Therapy
Description: We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
Study NCT05341830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery housing
Description: Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
Study NCT06387524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McConnell Taping
Description: Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
Study NCT06387524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECCENTRIC EXERCISES:
Description: Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch
Study NCT05671536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
Study NCT06522971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensiy interval training
Description: All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
Study NCT06464861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-NK/T
Description: Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
Study NCT05565768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-457
Description: HZN-457 will be given in one subcutaneous administration
Study NCT05565768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in one subcutaneous administration
Study NCT06201351 — intervention group
Intervention type: DEVICE
Intervention: adaptive radiotherapy
Description: MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Study NCT05760534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
Study NCT05760534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: 0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
Study NCT05133102 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Collection of saliva sample
Study NCT05992051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
Study NCT05992051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
Study NCT05314621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%)
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)
Study NCT05314621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Flonase® Allergy Relief (nasal spray)
Study NCT05314621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tears Naturale
Description: Tears Naturale® II (eye drop)
Study NCT05314621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline nasal spray
Description: Saline nasal spray (nasal spray)
Study NCT05262842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+IMP4297
Description: Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort.
Study NCT06465537 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD113vVLP
Description: CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
Study NCT05008003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines
Study NCT05008003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines
Study NCT05008003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A daily dose of 5000 IU vitamin D3 for 7 days.
Study NCT05168280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
Study NCT05168280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study NCT05524337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise
Description: Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db.
Study NCT05524337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
Study NCT05524337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise and therapeutic touch
Description: the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
Study NCT05054504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly iQ
Description: The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
Study NCT05033756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
Study NCT05033756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Tablet [Lynparza]
Description: All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
Study NCT06430086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut consumption
Description: Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
Study NCT06430086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCHS consumption
Description: Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality.
Study NCT05904210 — intervention group
Intervention type: DRUG
Intervention: SEVENFACT®
Description: Coagulation Factor VIIa (Recombinant)
Study NCT04704856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
Study NCT06755346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis plant (THC 20mg)
Description: Cannabis flower - very High THC (>10%) / Low CBD (\<1%)
Study NCT06755346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis (0%/ THC / 0% CBD)
Description: THC (0%) / CBD (0%) - Placebo marijuana
Study NCT05167903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
Study NCT05167903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
Study NCT06755346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis plant (THC 40mg)
Description: Cannabis flower - very High THC (>10%) / Low CBD (\<1%)
Study NCT06757010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE3107
Description: NE3107 20 mg BID
Study NCT06757010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT06758193 — intervention group
Intervention type: OTHER
Intervention: No intervention was applied in this study.
Description: No intervention was applied in this study.
Study NCT06755749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning Education
Description: Stage 1 (Day 1, 10-15 min): The education content for Session 1 in the FP Education Booklet prepared by the researchers was provided to the participants using the face-to-face interview method. After making an appointment for Stage 2 (Day 3) to be carried out at the FHC, the first stage of the data collection process was complete.~Stage 2 (Day 3, 10-15 min): The education content for Session 2 in the FP Education Booklet was provided to the participants who arrived at the FHC on their predetermined appointment days using the face-to-face interview method. After making an appointment for Stage 3 (Day 7) to be carried out at the FHC, the second stage of the data collection process was complete.~Stage 3 (Day 7, 1-5 min): The data collection forms were administered again to the participants who arrived at the FHC on their appointment days assigned at Stage 2, and the data collection process was complete.
Study NCT05829668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABA-based functional analysis and treatment
Description: Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
Study NCT05764395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Given by mouth
Study NCT05764395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV
Study NCT05764395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05764395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05435846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given orally
Study NCT05435846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given orally
Study NCT05083897 — intervention group
Intervention type: OTHER
Intervention: hip adduction isometric contraction
Description: addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
Study NCT05297773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group
Description: The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
Study NCT05297773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Group
Description: Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
Study NCT05297773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will perform a weekly stretching/relaxation session for 45 minutes.
Study NCT05021432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality training group
Description: This group will receive video based games
Study NCT05021432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit Training group
Description: They will receive Task-oriented Circuit training exercise program
Study NCT04698226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
Study NCT05764395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT04698226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole.
Study NCT05122559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
Study NCT05122559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF